SecBot SecBot

IART

INTEGRA LIFESCIENCES HOLDINGS CORP
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0000917520 Healthcare & Medical Devices
$12.10 +0.19 (+1.60%)
Oct 26 4:00 PM ET · prev $11.91
Market cap
$958.5M
Small cap
Consensus
Buy
44% Buy or better · 18 analysts
Median target
$14.00
+16% · range $13.00–23.00
1 year
−24.0%
from $15.93 · Oct 27
30 days
−25.6%
from $16.27
52-week range
$8.90–19.85
−39% from high · low Mar 18
Avg volume 20D
1.21M
shares / day
Short interest
7.27M
≈9.3% of shares · +6.8%
Days to cover
7.5
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 4 bearish · 0 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 9/9
Strongest BEARISH Integra LifeSciences reported Q3 2026 revenue of $411.2M (+2.3% YoY) and adjusted EPS of $0.59, missing…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 22 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    8 of 18 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.868 → $0.641 over 90 days. 0 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest +6.8% to 7.27M shares. 7.5 days to cover, ≈9.3% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCDOUBLED1,439,747$25.9M
Quantinno Capital Management LPADD609,132$10.9M
D. E. Shaw & Co., Inc.ADD507,252$9.1M
Nuveen, LLCDOUBLED485,458$8.7M
MARSHALL WACE, LLPDOUBLED349,737$6.3M
JPMORGAN CHASE & COTRIM214,504$4.0M
Assenagon Asset Management S.A.TRIM140,633$2.5M
UBS Group AGTRIM138,320$2.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 44% rate it Buy or better
Strong Buy4Buy4Hold8Sell2Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +16%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 26, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Oct 22, 2026Citigroup
MAINTAIN
MAINTAINNeutral
Oct 22, 2026BMO Capital
MAINTAIN
MAINTAINMarket Perform
Oct 22, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 22, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Oct 22, 2026JP Morgan
MAINTAIN
MAINTAINUnderweight

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 1, 2026
Veillon-Berteloot Chantal
EVP & CHRO
TAX W/H$24.2K
Jul 3, 2026
Knight Lea Daniels
EVP & Chief Financial Officer
TAX W/H$94.3K
Jul 1, 2026
Singh Harvinder
EVP & President, SS
AWARD5,590 sh
Jul 1, 2026
Mosebrook Jeffrey
SVP, Fin & Princ Acct Officer
TAX W/H$16.8K
Jul 1, 2026
DAVIS ROBERT T. JR.
EVP & President, TR&DT
AWARD11,180 sh
Jun 1, 2026
ESSIG STUART
President and CEO
AWARD705,468 sh
Jun 1, 2026
ESSIG STUART
President and CEO
AWARD365,297 sh
Jun 1, 2026
McBreen Michael J.
EVP & Chief Commercial Officer
AWARD60,372 sh

Earnings setup

Estimates
$0.64
EPS estimate, this quarter
−26%
estimate change, 90 days
0↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.64$0.62–$0.67-19.8%$422.4M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
7,266,960
shares short
+6.8%
vs prior settlement
7.5
days to cover
≈9.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Integra LifeSciences reported Q3 2026 revenue of $411.2M (+2.3% YoY) and adjusted EPS of $0.59, missing consensus…
8-K — Impact 6/10
Oct 21, 2026 Earnings result
IART Q3 2026 Earnings: EPS $0.59 (+3.0% vs est)
Oct 19, 2026 SEC
Integra LifeSciences entered into a comprehensive refinancing on October 19, 2026, replacing its existing credit…
8-K — Impact 6/10
Oct 14, 2026 SEC
This is a routine pretrial scheduling order in a civil case against Integra Lifesciences Corporation. The order sets…
COURT-RULING — Impact 2/10
Oct 14, 2026 Event
Penney v. Integra Lifesciences Corporation
Court ruling (cand) — Docket: 3:26-cv-07165
Sep 1, 2026 Insider
Veillon-Berteloot Chantal surrendered for taxes 1,455 shares
EVP & CHRO @ $16.62 ($24.2K)
Jul 3, 2026 Insider
Knight Lea Daniels surrendered for taxes 5,226 shares
EVP & Chief Financial Officer @ $18.05 ($94.3K)
Jul 1, 2026 Insider
Singh Harvinder was granted 5,590 shares
EVP & President, SS
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 21, 2026
Earnings result
IART Q3 2026 Earnings: EPS $0.59 (+3.0% vs est)
Oct 19, 2026
Press release
Integra Announces Completion of Refinancing Transactions
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a…
Oct 14, 2026
Enforcement
Penney v. Integra Lifesciences Corporation
Court ruling (cand) — Docket: 3:26-cv-07165
Oct 6, 2026
Earnings
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology…
Oct 2, 2026
Earnings
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology…

SecBot reports

16 filings · 1 press release · 1 bullish · 4 bearish · 3 mixed · 8 neutral
All IART filing & press-release reports (17)